ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Piet W. Boonstra
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boonstra, P. W.
Right arrow Articles by van Oeveren, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boonstra, P. W.
Right arrow Articles by van Oeveren, W.

Ann Thorac Surg 2004;78:1522
© 2004 The Society of Thoracic Surgeons

EDITORIAL

Clopidogrel and Postoperative Bleeding

Piet W. Boonstra, MD, PhDa,*, Wim van Oeveren, PhDb

a Department of Cardiothoracic Surgery, University Hospital of Groningen, Groningen, the Netherlands
b Department of Biomedical Engineering, Groningen University Medical Center, Groningen, the Netherlands

* Address reprint requests to Dr Boonstra, Department of Cardiothoracic Surgery, Groningen University Medical Center, Hanzeplein 1, 9713 EZ Groningen, the Netherlands (E-mail: p.w.boonstra@thorax.azg.nl).

The first 20% of the full text of this article appears below.

Clopidogrel,also known as Plavix, is an inhibitor of adenosine diphosphate–induced platelet aggregation (thienopyridine derivate). In combination with aspirin, which blocks the thromboxane-mediated pathway, it is recommended as the standard therapy for prevention of coronary artery stent thrombosis [1]. These two drugs ensure that platelet function will be inhibited and that stent thrombosis will be prevented. As a consequence of the widespread use of these drugs in treating acute coronary syndromes and using percutaneous coronary interventions, patients will have an increased risk of major bleeding [2]. In this issue of The Annals, Chu and associates prospectively assessed hemostasis after operations performed in 80 . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2004 by The Society of Thoracic Surgeons.